You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent ependymoma

Showing 1 - 25 of 7,857
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ependymoma Trial in Memphis, Toronto (radiation, procedure, drug, device)

Active, not recruiting
  • Ependymoma
  • Irradiation
  • +5 more
  • Memphis, Tennessee
  • +1 more
Oct 28, 2022

Recurrent Ependymoma Trial in Houston (5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group

Recruiting
  • Recurrent Ependymoma
  • 5-Azacytidine (5-AZA) group 1
  • +2 more
  • Houston, Texas
    The University of Texas Health Science Center at Houston
Aug 17, 2022

Ependymoma, Recurrent Childhood, Ependymoma Trial in Denver, Orlando (Granulocyte Macrophage Colony Stimulation Factor)

Active, not recruiting
  • Ependymoma, Recurrent Childhood
  • Ependymoma
  • Granulocyte Macrophage Colony Stimulation Factor
  • Denver, Colorado
  • +1 more
Feb 8, 2022

Posterior Fossa Ependymoma (PFEPN) Trial in Aurora (Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF)

Recruiting
  • Posterior Fossa Ependymoma (PFEPN)
  • Trastuzumab after SubQ GM-CSF
  • Trastuzumab in combination with SubQ GM-CSF
  • Aurora, Colorado
    Children's Hospital Colorado
Dec 2, 2021

Ependymoma Trial in New York (HER2 Specific CAR T Cell)

Recruiting
  • Ependymoma
  • HER2 Specific CAR T Cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Apr 6, 2022

Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma Trial in San Francisco, Ann Arbor, Zürich (ONC206, Standard of

Recruiting
  • Diffuse Midline Glioma (DMG)
  • +7 more
  • ONC206
  • Standard of Care Radiation Therapy
  • San Francisco, California
  • +2 more
Sep 13, 2022

Ependymoma Trial in Pittsburgh (biological, drug, other)

Recruiting
  • Ependymoma
  • HLA-A2 restricted synthetic tumor antigen
  • +5 more
  • Pittsburgh, Pennsylvania
    Children's Hospital of Pittsburgh of UPMC
Oct 23, 2022

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recruiting
  • Recurrent Childhood Acute Myeloid Leukemia
  • +17 more
    • Miami, Florida
      Nicklaus Children's Hospital
    May 13, 2023

    Ex Vivo Drug Sensitivity Testing and Mutation Profiling

    Completed
    • Recurrent Childhood Acute Myeloid Leukemia
    • +13 more
      • Miami, Florida
        Nicklaus Children's Hospital
      Jan 18, 2023

      CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

      Active, not recruiting
      • Central Nervous System Tumor, Pediatric
      • +8 more
      • EGFR806-specific chimeric antigen receptor (CAR) T cell
      • Seattle, Washington
        Seattle Children's Hospital
      Jan 18, 2023

      CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (HER2-specific chimeric antigen receptor (CAR) T cell)

      Recruiting
      • Central Nervous System Tumor, Pediatric
      • +8 more
      • HER2-specific chimeric antigen receptor (CAR) T cell
      • Seattle, Washington
        Seattle Children's Hospital
      Dec 14, 2022

      Malignant Glioma, Recurrent Ependymoma Trial in Chicago, Boston (biological, drug, radiation)

      Completed
      • Malignant Glioma
      • Recurrent Ependymoma
      • AdV-tk
      • +2 more
      • Chicago, Illinois
      • +1 more
      Oct 26, 2021

      Malignant Glioma, Ependymoma Trial in United States (Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields))

      Active, not recruiting
      • Malignant Glioma
      • +2 more
      • Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
      • Concurrent Optune and RT followed by Optune System alone
      • Los Angeles, California
      • +8 more
      Jan 17, 2023

      Ependymoma, Glioblastoma, Medulloblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR

      Recruiting
      • Ependymoma
      • +3 more
      • IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
      • Duarte, California
        City of Hope Medical Center
      Mar 9, 2022

      CNS Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma Trial in Seattle (SCRI-CARB7H3(s); B7H3-specific chimeric

      Recruiting
      • Central Nervous System Tumor
      • +10 more
      • SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
      • Seattle, Washington
        Seattle Children's Hospital
      Dec 14, 2022

      High Grade Glioma, Meningioma, Embryonal Tumor Trial in United States (LUTATHERA® (Lutetium Lu 177 dotatate))

      Recruiting
      • High Grade Glioma
      • +12 more
      • LUTATHERA® (Lutetium Lu 177 dotatate)
      • Aurora, Colorado
      • +8 more
      Jan 16, 2023

      Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, CNS Germ Cell Tumor Trial in Houston (drug, procedure, biological)

      Recruiting
      • Anaplastic Ependymoma
      • +14 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 17, 2022

      CNS Tumors, Glioblastoma, Gliosarcoma, Adult Trial run by the (ONC206)

      Recruiting
      • Central Nervous System Neoplasms
      • +22 more
      • Bethesda, Maryland
        National Institutes of Health
      Mar 1, 2022

      Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma Trial in United States (other, drug, procedure)

      Active, not recruiting
      • Anaplastic Astrocytoma
      • +6 more
      • Laboratory Biomarker Analysis
      • +4 more
      • Los Angeles, California
      • +11 more
      Jul 1, 2022

      Ependymoma, Ewing Sarcoma, High-grade Glioma Trial in Worldwide (Nivolumab, NKTR-214)

      Completed
      • Ependymoma
      • +9 more
      • Nivolumab
      • NKTR-214
      • Little Rock, Arkansas
      • +17 more
      Dec 8, 2022

      Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma Trial in Houston (Laboratory Biomarker

      Completed
      • Recurrent Childhood Medulloblastoma
      • +2 more
      • Laboratory Biomarker Analysis
      • Natural Killer Cell Therapy
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 31, 2020

      Brain Cancer, Pediatric Cancers Trial in United States (Bevacizumab, Lapatinib)

      Completed
      Has Results
      • Brain Cancer
      • Pediatric Cancers
      • Stanford, California
      • +5 more
      Aug 14, 2020

      Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto

      Recruiting
      • Malignant Solid Neoplasm
      • +26 more
      • Birmingham, Alabama
      • +121 more
      Aug 24, 2022

      Advanced Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial

      Recruiting
      • Advanced Malignant Solid Neoplasm
      • +30 more
      • Larotrectinib Sulfate
      • Birmingham, Alabama
      • +123 more
      Aug 23, 2022

      Advanced Malignant Solid Tumor, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

      Active, not recruiting
      • Advanced Malignant Solid Neoplasm
      • +31 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Birmingham, Alabama
      • +118 more
      Jan 27, 2023